CA018-005 Kidney Cancer

Full Name

A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants with Advanced Renal Cell Carcinoma (FRACTION-RCC)

Description

The purpose of this study is to test the effectiveness and safety of various nivolumab combinations compared to nivolumab and ipilimumab in participants with advanced kidney cancer

Eligibility

Inclusion Criteria
  • Advanced Renal Cell Carcinoma
  • Must have at least 1 lesion with measurable disease
  • Life expectancy of at least 3 months
Exclusion Criteria
  • Patients/subjects with suspected or known central nervous system metastases unless adequately treated
  • Patients/subjects with autoimmune disease
  • Patients/subjects who need daily oxygen therapy
  • Other protocol defined inclusion/exclusion criteria could apply
Doctor(s) Running This Study

Accepting New Patients

Specialties
Hematology/Medical Oncology
Area of focus
Melanoma
Kidney cancer (renal cancer)
Sarcoma
LVHN Affiliates
Lehigh Valley Cancer Institute
Locations

1240 S Cedar Crest Blvd
Suite 401
Allentown, PA 18103-6218
United States

181 East Brown Street
East Stroudsburg, PA 18301-3004
United States

Make an Appointment
Need help scheduling? Contact Us